Kennedy; Dana

Patent Applications and Registrations

Patent applications and USPTO patent grants for Kennedy; Dana.The latest application filed is for "weekly dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugates".

Company Profile

4.13.13

Kennedy; Dana - Bothell WA
Kennedy; Dana - Kirkland WA

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Weekly Dosing Regimens For Anti-cd30 Vc-pab-mmae Antibody Drug-conjugates App 20220288152 - Sievers; Eric ; et al.	2022-09-15
Weekly dosing regimens for anti-CD30 vc-PAB-MMAE antibody drug-conjugates Grant 11,369,658 - Sievers , et al. June 28, 2	2022-06-28
Weekly Dosing Regimens For Anti-cd30 Vc-pab-mmae Antibody Drug-conjugates App 20210315962 - Sievers; Eric ; et al.	2021-10-14
Combination of CD33 antibody drug conjugates with chemotherapeutic agents Grant 11,110,179 - Kennedy , et al. September 7, 2	2021-09-07
Weekly dosing regimens for anti-CD30 vc-PAB-MMAE antibody drug-conjugates Grant 11,077,164 - Sievers , et al. August 3, 2	2021-08-03
Weekly Dosing Regimens For Anti-cd30 Vc-pab-mmae Antibody Drug-conjugates App 20210138020 - Sievers; Eric ; et al.	2021-05-13
Weekly dosing regimens for anti-CD30 vc-PAB-MMAE antibody drug-conjugates Grant 10,940,178 - Sievers , et al. March 9, 2	2021-03-09
Weekly dosing regimens for anti-CD30 vc-PAB-MMAE antibody drug-conjugates Grant 10,912,813 - Sievers , et al. February 9, 2	2021-02-09
Weekly Dosing Regimens For Anti-cd30 Vc-pab-mmae Antibody Drug-conjugates App 20200306336 - Sievers; Eric ; et al.	2020-10-01
Humanized Anti-liv1 Antibodies For The Treatment Of Breast Cancer App 20200283540 - KENNEDY; Dana ; et al.	2020-09-10
Weekly dosing regimens for anti-CD30 vc-PAB-MMAE antibody drug-conjugates Grant 10,722,549 - Sievers , et al.	2020-07-28
Weekly Dosing Regimens For Anti-cd30 Vc-pab-mmae Antibody Drug-conjugates App 20200030405 - Sievers; Eric ; et al.	2020-01-30
Weekly dosing regimens for anti-CD30 vc-PAB-MMAE antibody drug-conjugates Grant 10,478,469 - Sievers , et al. Nov	2019-11-19
Weekly Dosing Regimens For Anti-cd30 Vc-pab-mmae Antibody Drug-conjugates App 20190224268 - SIEVERS; Eric ; et al.	2019-07-25
Combination Of Cd33 Antibody Drug Conjugates With Chemotherapeutic Agents App 20190134215 - Kennedy; Dana ; et al.	2019-05-09
Combinations Of Cd33 Antibody Drug Conjugates With Hypomethylating Agents App 20190117787 - Kennedy; Dana ; et al.	2019-04-25
Weekly Dosing Regimens For Anti-cd30 Vc-pab-mmae Antibody Drug-conjugates App 20180369317 - Sievers; Eric ; et al.	2018-12-27
Weekly dosing regimens for anti-CD30 VC-PAB-MMAE antibody drug-conjugates Grant 10,098,963 - Sievers , et al. October 16, 2	2018-10-16
Weekly Dosing Regimens For Anti-cd30 Vc-pab-mmae Antibody Drug-conjugates App 20170281794 - Sievers; Eric ; et al.	2017-10-05
Weekly dosing regimens for anti-CD30 VC-PAB-MMAE antibody drug-conjugates Grant 9,713,648 - Sievers , et al. July 25, 2	2017-07-25
Weekly Dosing Regimens For Anti-cd30 Vc-pab-mmae Antibody Drug-conjugates App 20160129130 - Sievers; Eric ; et al.	2016-05-12
Weekly dosing regimens for anti-CD30 VC-PAB-MMAE antibody drug-conjugates Grant 9,211,319 - Sievers , et al. December 15, 2	2015-12-15
Post-relapse treatment of CD30 expressing lymphomas Grant 8,758,758 - Sievers , et al. June 24, 2	2014-06-24
Weekly Dosing Regimens for Anti-CD30 VC-PAB-MMAE Antibody Drug-Conjugates App 20110268751 - Sievers; Eric ; et al.	2011-11-03

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.